Sunvozertinib price and where to buy

Sunvozertinib has been officially launched in mainland China and has been included in the National Reimbursement List for the treatment of patients with non-small cell lung cancer (NSCLC) carrying EGFR 20 exon insertion mutations (Exon 20ins). As a third-generation EGFR-TKI targeted drug independently developed in China, the launch of suvotinib has filled the gap in targeted treatment of this type of mutation in China. Thanks to the support of medical insurance, its price has dropped significantly compared with similar imported drugs, reducing the financial burden on patients.

In terms of price, the domestic market price of suvotinib is approximately more than 5,000 yuan per box. Specific prices vary by region and medical insurance reimbursement ratios. According to the national medical insurance policy, eligible patients can enjoy a certain proportion of expense reimbursement within the scope of the medical insurance catalog. The reimbursement rate in most areas can reach about 70%. Some cities or special disease outpatient clinics may also enjoy a higher proportion of reimbursement. It is recommended that patients go to the local hospital pharmacy or medical insurance department to consult the detailed reimbursement policy.

In terms of purchase channels, Suvotinib can currently be purchased at in-hospital pharmacies after directly issuing a prescription through the oncology or respiratory departments of many tertiary hospitals across the country. At the same time, some chain pharmacies or registered Internet hospital platforms can also purchase drugs online with a doctor's prescription, providing patients with convenient drug purchasing options. It should be noted that since suvotinib is a prescription drug, patients must be diagnosed and issued a prescription by a professional doctor before purchasing it. They are not allowed to use the drug privately or purchase products from unknown sources online.

Overall, suvotinib has great advantages in terms of price and accessibility, especially after being included in medical insurance, which better alleviates the financial pressure of patients taking the drug for a long time. In the future, with the continuous expansion of medical insurance coverage and further standardization of drug procurement platforms, the use of suvotinib will become more popular, and more patients who meet the indications will benefit from it. For patients who need to purchase medication, it is recommended to obtain medication guidance and services through formal medical channels to ensure medication safety and efficacy.

Reference materials:https://www.drugs.com/